Breaking down barriers to care in hepatitis C virus infection

Journal of Infectious Diseases

Volumn 213, Issue 7, 2016, Pages 1055-1056

  Thursz, Mark ^a   Lacombe, Karine ^b,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HÔPITAL SAINT ANTOINE   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

Dried blood spot; HCV; People who inject drugs (PWID); Resource limited countries; Viral load

Indexed keywords

DASABUVIR; HEPATITIS C ANTIBODY; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; VIRUS RNA;

DRIED BLOOD SPOT TESTING; GENOTYPING TECHNIQUE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; MOLECULAR DIAGNOSIS; NOTE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VIREMIA; VIRUS LOAD; BLOOD; FEMALE; HEPACIVIRUS; ISOLATION AND PURIFICATION; MALE; PROCEDURES; SPECIMEN HANDLING;

FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; MALE; RNA, VIRAL; SPECIMEN HANDLING;

EID: 84962622921     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv427     Document Type: Note

References (11)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2095-128.
2. Cooke GS, Lemoine M, Thursz M, et al. Viral hepatitis and the Global Burden of Disease: a need to regroup. J Viral Hepat 2013; 20:600-1.
3. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57:1333-42.
4. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889-98.
5. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/rombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370:1983-92.
6. Lemoine M, Thursz M. Viral hepatitis: Scaling up HCV treatment in resource-limited countries. Nat Rev Gastroenterol Hepatol 2015; 12:193-4.
7. Soulier A, Poiteau L, Rosa I, et al. Dried blood spots: a tool to ensure broad access to hepatitis C screening, diagnosis and treatment monitoring. J Infect Dis 2016; 213:1087-95.
8. Mederacke I, Wedemeyer H, Ciesek S, et al. Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. J Clin Virol 2009; 46:210-5.
9. Tuaillon E, Mondain AM, Meroueh F, et al. Dried blood spot for hepatitis C virus serology and molecular testing. Hepatology 2010; 51:752-8.
10. Sidharthan S, Kohli A, Sims Z, et al. Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. Clin Infect Dis 2015; 60:1743-51.
11. McLeod A, Weir A, Aitken C, et al. Rise in testing and diagnosis associated with Scotland's Action Plan on Hepatitis C and introduction of dried blood spot testing. J Epidemiol Community Health 2014; 68:1182-8.